Heart Rate Variability and Recurrent Stroke and Myocardial Infarction in Patients With Acute Mild to Moderate Stroke.

Front Neurol

Klinik und Hochschulambulanz für Neurologie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.

Published: December 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In patients with acute ischemic stroke, reduced heart rate variability (HRV) may indicate poor outcome. We tested whether HRV in the acute phase of stroke is associated with higher rates of mortality, recurrent stroke, myocardial infarction (MI) or functional outcome. Patients with acute mild to moderate ischemic stroke without known atrial fibrillation were prospectively enrolled to the investigator-initiated Heart and Brain interfaces in Acute Ischemic Stroke (HEBRAS) study (NCT02142413). HRV parameters were assessed during the in-hospital stay using a 10-min section of each patient's ECG recording at day- and nighttime, calculating time and frequency domain HRV parameters. Frequency of a combined endpoint of recurrent stroke, MI or death of any cause and the respective individual events were assessed 12 months after the index stroke. Patients' functional outcome was measured by the modified Rankin Scale (mRS) at 12 months. We included 308 patients (37% female, median NIHSS = 2 on admission, median age 69 years). Complete follow-up was achieved in 286/308 (93%) patients. At 12 months, 32 (9.5%), 5 (1.7%) and 13 (3.7%) patients had suffered a recurrent stroke, MI or death, respectively. After adjustment for age, sex, stroke severity and vascular risk factors, there was no significant association between HRV and recurrent stroke, MI, death or the combined endpoint. We did not find a significant impact of HRV on a mRS ≥ 2 12 months after the index stroke. HRV did not predict recurrent vascular events in patients with acute mild to moderate ischemic stroke.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733333PMC
http://dx.doi.org/10.3389/fneur.2021.772674DOI Listing

Publication Analysis

Top Keywords

recurrent stroke
20
patients acute
16
ischemic stroke
16
stroke
14
acute mild
12
mild moderate
12
stroke death
12
heart rate
8
rate variability
8
stroke myocardial
8

Similar Publications

Introduction: Recent studies in stroke patients from predominantly Asian populations have underscored the significance of trimethylamine N-oxide (TMAO) as a valuable blood biomarker for predicting incident strokes and major adverse cardiovascular events (MACE). However, its prognostic role after ischemic stroke in other populations is not yet comprehensively investigated.

Patients And Methods: We measured plasma TMAO levels in 1726 acute ischemic stroke patients (within 24 h from symptom onset) from the multicenter BIOSIGNAL cohort.

View Article and Find Full Text PDF

Objective: Non-acute subdural hematomas (NASDHs) often recur or persist, particularly among older patients with comorbidities. Middle meningeal artery embolization (MMAe) has emerged as a promising primary treatment alternative. Dual-lumen balloon microcatheters significantly reduce the risk of reflux, which is a limitation of single-lumen microcatheters.

View Article and Find Full Text PDF

Naoxintong Capsules for Secondary Prevention of Ischemic Stroke: Meta-Analyses of Clinical and Preclinical Evidence.

J Ethnopharmacol

September 2025

Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. Electronic address:

Ethnopharmacological Relevance: Naoxintong, a Chinese patent medicine, may serve as an adjunctive therapy for the secondary prevention of ischemic stroke.

Aim Of The Study: To assess the effectiveness and safety of Naoxintong in preventing recurrent ischemic stroke and to review its preclinical evidence.

Materials And Methods: A search of electronic databases and registries was performed to locate relevant randomized controlled trials (RCTs) on Naoxintong for preventing ischemic stroke recurrence and animal studies exploring its mechanisms in atherosclerosis improvement.

View Article and Find Full Text PDF

Multicenter Practice of Non/Minimized Fluoroscopy Ablation for Paroxysmal AF in China: The PAF-ICE Trial.

JACC Asia

August 2025

Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; Comprehensive Unit of National Regional Medical Center, Zhejiang Province, China. Electronic address:

Background: Intracardiac echocardiography (ICE)-guided non/minimized-fluoroscopy catheter ablation for atrial fibrillation (AF) has been reported, but its effectiveness and safety still lack multicenter evidence.

Objectives: The authors sought to evaluate the effectiveness and safety of ICE-guided non/minimized-fluoroscopy catheter ablation compared with the traditional fluoroscopy-guided approach in patients with paroxysmal AF.

Methods: A total of 448 patients with paroxysmal AF, from 15 centers in China, were randomly assigned in a 1:1 ratio to a non/minimized-fluoroscopy group (n = 223) and a traditional approach group (n = 225).

View Article and Find Full Text PDF

Purpose: Endovascular treatment of intracranial atherosclerotic disease (ICAD) remains challenging due to procedural risks and stroke recurrence. Previous trials have favored aggressive medical therapy. In patients refractory to medical therapy, 'stentplasty' using expandable and retrievable devices may provide a safer alternative to balloon angioplasty by allowing controlled submaximal vessel dilation without flow arrest.

View Article and Find Full Text PDF